Protara Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Protara Therapeutics (TARA).

Price Target Range — 9 Quarters

Analyst Consensus — 8 Analysts

8Buy

Consensus RatingBuy# Analysts8Avg. Consensus PT$23Upside to Avg. PT+843.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
May 20, 2026	Oppenheimer	Leland Gershell	PT Raise	Outperform	$25→$28
May 14, 2026	JP Morgan	Brian Cheng	PT Cut	Overweight	$27→$26
Apr 29, 2026	HC Wainwright & Co.	Andrew S. Fein	PT Raise	Buy	$23→$27
Mar 4, 2026	JP Morgan	Brian Cheng	Initiate	Overweight	$27
Feb 10, 2026	HC Wainwright & Co.	Andres Y. Maldonado	Maintained	Buy	$23
Jan 7, 2026	Piper Sandler	Kelsey Goodwin	Initiate	Overweight	$24
Dec 3, 2025	HC Wainwright & Co.	Andres Y. Maldonado	Maintained	Buy	$23
Nov 19, 2025	HC Wainwright & Co.	Andres Y. Maldonado	Maintained	Buy	$23
May 22, 2025	Jones Trading	Soumit Roy	Initiate	Buy	$21
Apr 28, 2025	HC Wainwright & Co.	Andres Maldonado	Maintained	Buy	$23
Apr 16, 2025	Scotiabank	George Farmer	Initiate	Sector Outperform	$12
Mar 14, 2025	Cantor Fitzgerald	Li Watsek	Initiate	Overweight	—
Mar 11, 2025	LifeSci Capital	—	Initiate	Outperform	$22
Mar 6, 2025	HC Wainwright & Co.	Andrew Fein	Maintained	Buy	$23
Dec 6, 2024	Guggenheim	Michael Schmidt	Maintained	Buy	$20
Dec 6, 2024	HC Wainwright & Co.	Andrew Fein	Maintained	Buy	$23
Nov 14, 2024	HC Wainwright & Co.	Andrew Fein	Maintained	Buy	$23
Aug 12, 2024	Oppenheimer	Leland Gershell	PT Cut	Outperform	$30→$25
Aug 8, 2024	HC Wainwright & Co.	Andrew Fein	Maintained	Buy	$23
May 6, 2024	HC Wainwright & Co.	Andrew Fein	Maintained	Buy	$23

Analyst Ratings News

PRO
Oppenheimer Maintains Outperform on Protara Therapeutics, Raises Price Target to $28

Oppenheimer analyst Leland Gershell maintains Protara Therapeutics (NASDAQ:TARA) with a Outperform and raises the price target from $25 to $28.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Protara Therapeutics, Lowers Price Target to $26

JP Morgan analyst Brian Cheng maintains Protara Therapeutics (NASDAQ:TARA) with a Overweight and lowers the price target from $27 to $26.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Protara Therapeutics, Raises Price Target to $27

HC Wainwright & Co. analyst Andrew S. Fein maintains Protara Therapeutics (NASDAQ:TARA) with a Buy and raises the price target from $23 to $27.

Benzinga Newsdesk

PRO
JP Morgan Initiates Coverage On Protara Therapeutics with Overweight Rating, Announces Price Target of $27

JP Morgan analyst Brian Cheng initiates coverage on Protara Therapeutics (NASDAQ:TARA) with a Overweight rating and announces Price Target of $27.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Protara Therapeutics, Maintains $23 Price Target

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Protara Therapeutics (NASDAQ:TARA) with a Buy and maintains $23 price target.

Benzinga Newsdesk

PRO
Piper Sandler Initiates Coverage On Protara Therapeutics with Overweight Rating, Announces Price Target of $24

Piper Sandler analyst Kelsey Goodwin initiates coverage on Protara Therapeutics (NASDAQ:TARA) with a Overweight rating and announces Price Target of $24.

Benzinga Newsdesk

Protara Therapeutics Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Protara Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Oppenheimer Maintains Outperform on Protara Therapeutics, Raises Price Target to $28

PRO
JP Morgan Maintains Overweight on Protara Therapeutics, Lowers Price Target to $26

PRO
HC Wainwright & Co. Maintains Buy on Protara Therapeutics, Raises Price Target to $27

PRO
JP Morgan Initiates Coverage On Protara Therapeutics with Overweight Rating, Announces Price Target of $27

PRO
HC Wainwright & Co. Reiterates Buy on Protara Therapeutics, Maintains $23 Price Target

PRO
Piper Sandler Initiates Coverage On Protara Therapeutics with Overweight Rating, Announces Price Target of $24

People Also Watch

People Also Watch

Protara Therapeutics Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Protara Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROOppenheimer Maintains Outperform on Protara Therapeutics, Raises Price Target to $28

PROJP Morgan Maintains Overweight on Protara Therapeutics, Lowers Price Target to $26

PROHC Wainwright & Co. Maintains Buy on Protara Therapeutics, Raises Price Target to $27

PROJP Morgan Initiates Coverage On Protara Therapeutics with Overweight Rating, Announces Price Target of $27

PROHC Wainwright & Co. Reiterates Buy on Protara Therapeutics, Maintains $23 Price Target

PROPiper Sandler Initiates Coverage On Protara Therapeutics with Overweight Rating, Announces Price Target of $24

People Also Watch

People Also Watch

PRO
Oppenheimer Maintains Outperform on Protara Therapeutics, Raises Price Target to $28

PRO
JP Morgan Maintains Overweight on Protara Therapeutics, Lowers Price Target to $26

PRO
HC Wainwright & Co. Maintains Buy on Protara Therapeutics, Raises Price Target to $27

PRO
JP Morgan Initiates Coverage On Protara Therapeutics with Overweight Rating, Announces Price Target of $27

PRO
HC Wainwright & Co. Reiterates Buy on Protara Therapeutics, Maintains $23 Price Target

PRO
Piper Sandler Initiates Coverage On Protara Therapeutics with Overweight Rating, Announces Price Target of $24